Flex­ion se­cures Chi­na deal for os­teoarthri­tis drug; Strug­gling to find a buy­er, Ako­rn throws in the tow­el

→ Flex­ion may be hit­ting the brakes on clin­i­cal tri­als, in­clud­ing one for its os­teoarthri­tis drug Zil­ret­ta, but that’s not stop­ping the biotech from plot­ting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER